CRYSTMAS study adds to concerns about renal safety and increased mortality in sepsis patients

Critical Care

Volumn 16, Issue 6, 2012, Pages

  Hartog, Christiane S ^a   Reinhart, Konrad ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH; SODIUM CHLORIDE; HETASTARCH DERIVATIVE;

ACUTE KIDNEY FAILURE; CRYSTALLOID; FLUID RESUSCITATION; HUMAN; KIDNEY FUNCTION; LETTER; MORTALITY; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; SEPSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; DRUG EFFECTS; FEMALE; FLUID THERAPY; HEMODYNAMICS; MALE; PROCEDURES;

FEMALE; FLUID THERAPY; HEMODYNAMICS; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; MALE; SEPSIS; SODIUM CHLORIDE;

EID: 84868626474     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11673     Document Type: Letter

References (6)

1. Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, Forceville X, Feissel M, Hasselmann M, Heininger A, Van Aken H. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Crit Care 2012, 16:R94. 10.1186/cc11358, 22624531.
2. Perner A, Haase N, Wetterslev J, Aneman A, Tenhunen J, Guttormsen AB, Klemenzson G, Pott F, Bødker KD, Bådstøløkken PM, Bendtsen A, Søe-Jensen P, Tousi H, Bestle M, Pawlowicz M, Winding R, Bülow HH, Kancir C, Steensen M, Nielsen J, Fogh B, Madsen KR, Larsen NH, Carlsson M, Wiis J, Petersen JA, Iversen S, Schøidt O, Leivdal S, Berezowicz P, et al. Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S - Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial. Trials 2011, 12:24. 10.1186/1745-6215-12-24, 3040153, 21269526.
3. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K, . German Competence Network Sepsis (SepNet) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:125-139. 10.1056/NEJMoa070716, 18184958, German Competence Network Sepsis (SepNet).
4. Package insert Voluven. , http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/NewDrugApplicationsNDAs/UCM083138.pdf
5. McGauran N, Wieseler B, Kreis J, Schuler YB, Kolsch H, Kaiser T. Reporting bias in medical research - a narrative review. Trials 2010, 11:37. 10.1186/1745-6215-11-37, 2867979, 20388211.
6. Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis (CRYSTMAS). NLM Identifier: NCT00464204. , http://clinicaltrials.gov/ct2/show/study/NCT00464204?sect=Xji8015